Gilead Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Gilead Sciences has a total shareholder equity of $18.4B and total debt of $23.2B, which brings its debt-to-equity ratio to 126.4%. Its total assets and total liabilities are $54.5B and $36.1B respectively. Gilead Sciences's EBIT is $11.2B making its interest coverage ratio 16.4. It has cash and short-term investments of $6.7B.
Key information
126.4%
Debt to equity ratio
US$23.25b
Debt
| Interest coverage ratio | 16.4x |
| Cash | US$6.70b |
| Equity | US$18.39b |
| Total liabilities | US$36.13b |
| Total assets | US$54.53b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GILD34's short term assets ($14.8B) exceed its short term liabilities ($11.7B).
Long Term Liabilities: GILD34's short term assets ($14.8B) do not cover its long term liabilities ($24.4B).
Debt to Equity History and Analysis
Debt Level: GILD34's net debt to equity ratio (90%) is considered high.
Reducing Debt: GILD34's debt to equity ratio has increased from 118.6% to 126.4% over the past 5 years.
Debt Coverage: GILD34's debt is well covered by operating cash flow (43.1%).
Interest Coverage: GILD34's interest payments on its debt are well covered by EBIT (16.4x coverage).